SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

12 Nov 2025 Evaluate
The sales slipped to Rs. 9.19 millions, down -64.28% for the September 2025 quarter as against Rs. 25.73 millions during the year-ago period.The Net Loss for the quarter ended September 2025 is Rs. -154.45 millions as compared to Net Loss of Rs. -110.72 millions of corresponding quarter ended September 2024 Operating profit Margin for the quarter ended September 2025 further decreased to -141.28% as compared to -96.01% of corresponding quarter ended September 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 9.19 25.73 -64.28 27.86 35.79 -22.16 66.56 116.93 -43.08
Other Income 37.78 40.35 -6.37 43.67 79.66 -45.18 107.26 211.30 -49.24
PBIDT -141.28 -96.01 47.15 -275.38 -157.58 74.76 -412.11 -98.07 320.22
Interest 0.00 0.16 0.00 0.00 0.39 0.00 0.47 1.58 -70.25
PBDT -141.28 -96.17 46.91 -275.38 -157.97 74.32 -412.58 -25.08 1545.06
Depreciation 13.17 14.55 -9.48 26.85 29.41 -8.70 58.22 65.02 -10.46
PBT -154.45 -110.72 39.50 -302.23 -187.38 61.29 -470.80 -90.10 422.53
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.02 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -154.45 -110.72 39.50 -302.23 -187.38 61.29 -470.80 -80.08 487.91
Equity 227.47 218.07 4.31 227.47 218.07 4.31 218.07 218.07 0.00
PBIDTM(%) -1537.32 -373.14 311.99 -988.44 -440.29 124.50 -619.16 -83.87 638.23

Suven Life Sciences Share Price

194.65 16.35 (9.17%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×